Theracryf Plc (AIM:TCF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2250
0.00 (0.00%)
Apr 25, 2025, 12:43 PM GMT+1
-71.88%
Market Cap 4.79M
Revenue (ttm) n/a
Net Income (ttm) -2.92M
Shares Out 2.13B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 118,218
Average Volume 1,167,859
Open 0.2500
Previous Close 0.2250
Day's Range 0.2250 - 0.2500
52-Week Range 0.2000 - 1.2500
Beta 1.87
RSI 29.58
Earnings Date May 28, 2025

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addict... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange London Stock Exchange AIM
Ticker Symbol TCF
Full Company Profile

Financial Performance

In 2023, Theracryf's revenue was 396,000, a decrease of -10.41% compared to the previous year's 442,000. Losses were -3.14 million, -22.41% less than in 2022.

Financial Statements

News

There is no news available yet.